Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N-Acetyl GM3 vaccine - Recombio

Next Previous
X
Search
Drug Profile

N-Acetyl GM3 vaccine - Recombio

Alternative Names: N-acetil GM3/VSSP; NAcetilGM3; NAcGM3-VSSP vaccine

Latest Information Update: 16 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Elea
  • Class AIDS vaccines; Cancer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections
  • Discontinued Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma

Most Recent Events

  • 16 Apr 2021 N-Acetyl GM3 vaccine is still in phase I/II trial for HIV infections in Cuba (SC) (RPCEC00000213)
  • 16 Apr 2021 NDR batch#20: The trial record is still showing 'recruiting status'. so based on this, added ADS. Discussed this with SME
  • 18 Mar 2011 Clinical development is ongoing for Cancer and HIV infections in Cuba and Argentina

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top